01 Biomarker-Based Response Tracking Moving into Neoadjuvant Chemotherapy Molecular response assessment is becoming more relevant when clinicians need earlier evidence of how tumors react during chemotherapy. Blood-based biomarkers such as circulating tumor DNA are being studied alongside imaging to track treatment response; an active NCI-listed pancreatic cancer study measures ctDNA before, during, and after neoadjuvant chemotherapy to assess DNA clearance. This approach could support more individualized treatment monitoring and provide clinicians with molecular information before conventional post-treatment evaluation.
02 Solvent-Free Liposomal Taxane Formulations Addressing Delivery Limitations Solubility and solvent-related toxicity remain important formulation challenges for taxane chemotherapy agents such as docetaxel. Liposomal delivery offers an alternative by encapsulating docetaxel without solvents such as Tween 80 while supporting tumor penetration and longer drug exposure; the NCI notes that this formulation can also avoid solvent-associated hypersensitivity reactions. This approach places formulation technology at the center of efforts to improve tolerability and delivery efficiency for established chemotherapy molecules.
01 Wider Use of Chemotherapy in Combination Regimens and Higher Use of Chemotherapy in Hematologic Malignancies Drive Market Broader use of chemotherapy alongside immunotherapy, targeted agents, surgery, and radiation increases demand for cytotoxic drugs across multiple treatment pathways. Combination regimens allow oncologists to attack tumors through different mechanisms and often keep chemotherapy as a core component even when newer therapies are added. Treatment protocols for cancers such as breast, lung, and colorectal cancer commonly pair chemotherapy with other systemic therapies. This demand-side transition sustains chemotherapy volumes across both established and evolving oncology regimens.Continued reliance on chemotherapy for leukemia, lymphoma, and other hematologic malignancies supports steady demand for injectable and oral cytotoxic agents. Many blood cancer treatment protocols still use multi-drug chemotherapy to induce remission, control disease progression, or prepare patients for stem-cell transplantation. Hospital oncology units and specialized hematology centers therefore maintain recurring procurement of drugs such as cyclophosphamide, cytarabine, and anthracyclines. This demand-side transition preserves a strong chemotherapy requirement across hematologic cancer treatment.
01 Drug Resistance and Variable Treatment Response and Limited Access to Oncology Infrastructure in Underserved Regions Tumor resistance and differences in patient response can reduce the effectiveness of chemotherapy across treatment cycles. Lower or inconsistent outcomes may require dose changes, combination regimens, or a switch to other therapies. This limits long-term reliance on chemotherapy and restrains broader market growth.Many underserved regions lack oncology specialists, infusion centers, diagnostic support, and monitoring facilities needed for chemotherapy treatment. Limited infrastructure reduces the number of patients who can receive and complete therapy safely. This access gap restricts treatment reach and slows market expansion.
01 Development of Safer Closed-System Drug-Transfer and Handling Solutions for Oncology Centers and Expansion of Chemotherapy Services in Ambulatory Oncology and Day-Care Centers Oncology hospitals, infusion centers, pharmacy departments, and chemotherapy compounding units represent the main customer groups for this opportunity. Closed-system transfer devices, protective handling kits, and pharmacy-safety solutions can create revenue through equipment sales, consumables, training, and recurring replacement products. Companies such as BD, ICU Medical, and Equashield are well positioned through established hazardous-drug handling portfolios.Ambulatory oncology centers, day-care hospitals, specialty cancer clinics, and infusion networks form the key customer base for this opportunity. Outpatient chemotherapy models can create revenue through infusion services, treatment packages, pharmacy support, patient monitoring, and recurring care programs. Companies such as McKesson, Fresenius, and major oncology clinic networks are positioned to participate through established cancer-care and infusion capabilities.
01 Persistent Shortages of Generic Injectable Chemotherapy Drugs and Complexity of Maintaining Reliable Sterile Manufacturing Capacity Chemotherapy providers and manufacturers face recurring supply disruptions because many established oncology drugs depend on a small number of sterile-injectable production lines and suppliers. Shortages disrupt treatment scheduling, complicate procurement, and force hospitals to manage limited inventories or substitute regimens. In June 2026, ASHP identified ifosfamide as a particularly severe chemotherapy shortage caused by manufacturing-quality problems at a key supplier.Chemotherapy production requires tightly controlled sterile manufacturing, quality assurance, and specialized facilities, making rapid capacity recovery difficult when a plant experiences operational problems. FDA notes that long production lead times and limited manufacturing capacity make older sterile injectable medicines particularly vulnerable when one supplier encounters production problems.
July 2025 Dizal Pharmaceutical received U.S. FDA accelerated approval for Zegfrovy® (sunvozertinib) for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease progressed after platinum-based chemotherapy. The approval highlighted continued development of targeted therapies used alongside or after chemotherapy treatments.
July 2025 The U.S. FDA expanded approvals for oncology therapies involving patients previously treated with chemotherapy, including novel targeted and immune-based treatments. These regulatory developments reflected increasing integration of chemotherapy with newer treatment modalities such as targeted therapies and antibody-based approaches.
June 2025 Daiichi Sankyo received U.S. FDA accelerated approval for Datroway® (datopotamab deruxtecan-dlnk), an antibody-drug conjugate (ADC), for adults with EGFR-mutated non-small cell lung cancer (NSCLC) who previously received EGFR-directed therapy and platinum-based chemotherapy. The approval expanded treatment options for patients with advanced lung cancer following chemotherapy-based regimens.
June 2025 Daiichi Sankyo continued expanding its oncology portfolio through the advancement of antibody-drug conjugate therapies designed to provide targeted delivery of anticancer agents. The company’s ADC platform development supported the shift toward combination approaches involving chemotherapy-derived payload technologies and precision oncology strategies.